BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2024 8:41:18 AM | Browse: 56 | Download: 249
 |
Received |
|
2024-06-05 11:05 |
|
Peer-Review Started |
|
2024-06-05 11:05 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-06-25 10:56 |
|
Revised |
|
2024-07-03 03:59 |
|
Second Decision |
|
2024-07-09 02:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-07-09 06:45 |
|
Articles in Press |
|
2024-07-09 06:45 |
|
Publication Fee Transferred |
|
2024-07-14 16:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-29 09:21 |
|
Publish the Manuscript Online |
|
2024-09-09 08:41 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cheng-Wan Zheng, Yun-Mo Yang and Hui Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hui Yang, MMed, Chief Physician, Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. yh65011@163.com |
| Key Words |
Advanced gastric cancer; Oxaliplatin; Trastuzumab; Serum tumor markers; T lymphocyte subsets; Predictive biomarkers |
| Core Tip |
An investigation of the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with advanced gastric cancer (AGC) revealed significant reductions in carcinoembryonic antigen, cancer antigen 19-9, and cancer antigen 72-4 levels, as well as favorable changes in T cell populations. Patients with significantly decreased tumor marker levels and increased CD4+/CD8+ ratio exhibited better treatment responses. The therapy not only targets tumors but also boosts immune responses in patients with AGC. Serum markers and T cell subsets are potential predictive biomarkers for treatment outcomes in patients with AGC receiving this combined treatment. |
| Publish Date |
2024-09-09 08:41 |
| Citation |
<p>Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. <i>World J Gastrointest Oncol</i> 2024; 16(9): 3905-3912</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i9.3905 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
